People with diffuse B cell lymphoma (DLBCL) – a type of non-Hodgkin lymphoma – are usually treated with chemotherapy and a biological therapy called rituximab. Although this approach works for many people, sometimes the treatment isn’t effective, or the lymphoma comes back.
This trial is looking at a new drug called vistusertib for people with DLBCL that has continued to grow during standard treatment, or has come back afterwards. Vistusertib is a type of biological therapy and prevents cancer cells from growing by targeting the mTOR pathway, blocking the signals that cancer cells use to divide and grow.
Rituximab is a type of biological therapy called a monoclonal antibody. It works by targeting a protein called CD20, which is found on the surface of healthy white blood cells and abnormal white blood cells that occur in leukaemia and lymphoma. The monoclonal antibody binds to all the cells that have CD20 on their surface, which triggers the immune system to attack the marked cells and kill them. Rituximab causes both healthy and cancerous white blood cells to be destroyed, but the body can replenish the healthy white blood cells once the treatment is over.
Researchers want to know if vistersertib is effective and safe for people with relapsed DLBCL. They also want to know if giving rituximab alongside vistusertib provides any additional benefit, so will be testing this drug combination in a small number of people.
The aims of this trial are to:
- Find out If vistusertib helps people with DLBCL
- Find out if combining vistusertib with rituximab is a useful and safe treatment
- Learn more about the side effects of the combination therapy
This trial is closed for recruitment, and we hope to update you with the results soon.